This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Genotoxicity Remove Hormones Remove Nurses Related Topics
Bioassay Gene Expression Insulin Cardiology Regulation Clinical Trials Containment Clinical Research Medicine Trials More Related Topics >
article thumbnail

FIRST-LINE IBRANCE® (PALBOCICLIB) COMBINATION THERAPY IN HR+, HER2- METASTATIC BREAST CANCER

The Pharma Data

MARCH 25, 2021

IBRANCE may impair fertility in males and has the potential to cause genotoxicity. Advise women not to breastfeed during IBRANCE treatment and for 3 weeks after the last dose because of the potential for serious adverse reactions in nursing infants. Advise male patients to consider sperm preservation before taking IBRANCE.

HR 52
HR Clinical Trials Clinical Trials Trials 52
article thumbnail

Let's Quit Sugar With Audiobook – Let's Quit Sugar

The Pharma Data

MAY 13, 2021

Following this program will help you lose weight fast, prevent yo-yoing, stabilize hormonal balance, and get back on track to leading a healthy life – all while never being hungry or having to go to the gym! Effects of glucose-to-fructose ratios in solutions on subjective satiety, food intake, and satiety hormones in young men.

Insulin 52
Insulin Production Hormones Medicine 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 32,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024